Novartis, Amgen partner on Alzheimer's, migraine treatment

Swiss drug maker Novartis says it will cooperate with California-based biotech giant Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches.

A Novartis statement released late Tuesday said that as part of the deal, Amgen will make initial payments and cover some research and development costs at the start with regard to the BACE inhibitor program for treatment of Alzheimer's. That will be followed by a 50-50 cost and profit sharing arrangement.

As for migraine, Novartis will fund some R&D expenses for an agreed period and pay Amgen double-digit royalties on sales. The Basel-based company will also receive some commercialization and co-development rights to "the investigative molecules in Amgen's migraine portfolio."

Specific financial terms were not disclosed.


Explore further

Court ruling clears way for Novartis' low-cost biotech drug

© 2015 The Associated Press. All rights reserved.

Citation: Novartis, Amgen partner on Alzheimer's, migraine treatment (2015, September 2) retrieved 21 October 2021 from https://medicalxpress.com/news/2015-09-novartis-amgen-partner-alzheimer-migraine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
12 shares

Feedback to editors